Ameritox's Midland, Texas, facility welcomed Congressman Mike Conaway (R-TX) of the 11th District for a tour of the laboratory. Currently, Ameritox employs nearly 230 people in the greater Midland area at both its laboratory facility and at its new administrative facility in downtown Midland.
"We're honored to be a partner in the communities where our facilities are located," said Lopes of Ameritox. "Our technology is dependent on skilled workers and we're fortunate to be located in two hubs where skilled workers abound."
Ameritox secured licensing rights from Marshfield Clinic to continue developing a new technology to assist in determining the likelihood of patient adherence. Ameritox will further develop this technology for commercialization and support additional research and development, greatly expanding the scope and usability of pain medication monitoring among its physician partners.
Adding to considerable bench strength within the company, the Ameritox team has grown significantly to enhance support for the company's physician partners across the nation.
As a further benefit to both the physician service and leading Medical Science Liaison team for which it is known, Ameritox has appointed Kathryn S. Bronstein, PhD, RN, as Director of Medical Science and Health Outcomes, and expanded its Medical Science Liaison team with the additions of David E. Chapman, PhD; Monica A. Fay, PharmD., MBA; Lisa M. Burke, PhD, MBA, RN; and Barry Cohen, PhD as Assistant Directors of Medical Science and Health Outcomes Research. Kendra L. Davies, B.S., PharmD, also joined as Associate Director, Medical Affairs, rounding out a team focused on maintaining the highest level of clinical and research rigor in the industry.
The company has also formed a new Government Programs department to expand support to public health care providers who manage patients on chronic opioid therapy.